Prediction of progression-free survival rates after bevacizumab plus interferon versus interferon alone in patients with metastatic renal cell carcinoma: comparison of a nomogram to the Motzer criteria.

@article{Karakiewicz2011PredictionOP,
  title={Prediction of progression-free survival rates after bevacizumab plus interferon versus interferon alone in patients with metastatic renal cell carcinoma: comparison of a nomogram to the Motzer criteria.},
  author={Pierre I. Karakiewicz and Maxine Sun and Joaquin Bellmunt and Vesna Sneller and Bernard Escudier},
  journal={European urology},
  year={2011},
  volume={60 1},
  pages={48-56}
}
BACKGROUND The combination of bevacizumab plus interferon (BEV+IFN) for treatment of metastatic renal cell carcinoma (mRCC) is associated with improved progression-free survival (PFS) in a phase 3 study. OBJECTIVE To develop a novel model for prediction of individual PFS using data from the randomized, controlled phase 3 trial of BEV + IFN or interferon alone. The ability of the Motzer criteria for prediction of PFS was also assessed. DESIGN, SETTING, AND PARTICIPANTS Pretreatment… CONTINUE READING